Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

Moderna's mRNA-based pandemic flu vaccine – which had federal funding pulled earlier this year amid an increasingly vaccine-sceptic stance by the Trump administration – has been thrown a lifeline by ...

Obesity is more than a number on the scale - it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers. The need for innovative solutions has never been ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made available ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

The clinical research environment has undergone considerable transformation over the past decade. Protocols are more complex, product pipelines increasingly target smaller and more distributed patient ...

Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...

The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma. The latest voucher in the controversial ...